Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	B:C0014432
for	O
aldose	O
reductase	I:C0002003
(	O
ALR2	O
)	O
and	O
poly	O
(	I:C0032405
ADP	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
PARP	O
-	I:C0032405
1	I:C0032405
)	O
using	O
structure	O
based	O
design	O
approach	O
.	O

Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	O
for	O
aldose	B:C0002003
reductase	I:C0002003
(	O
ALR2	O
)	O
and	O
poly	O
(	I:C0032405
ADP	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
PARP	O
-	I:C0032405
1	I:C0032405
)	O
using	O
structure	O
based	O
design	O
approach	O
.	O

Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	O
for	O
aldose	O
reductase	I:C0002003
(	O
ALR2	B:C0002003
)	O
and	O
poly	O
(	I:C0032405
ADP	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
PARP	O
-	I:C0032405
1	I:C0032405
)	O
using	O
structure	O
based	O
design	O
approach	O
.	O

Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	O
for	O
aldose	O
reductase	I:C0002003
(	O
ALR2	O
)	O
and	O
poly	B:C0032405
(	I:C0032405
ADP	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
PARP	O
-	I:C0032405
1	I:C0032405
)	O
using	O
structure	O
based	O
design	O
approach	O
.	O

Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	O
for	O
aldose	O
reductase	I:C0002003
(	O
ALR2	O
)	O
and	O
poly	O
(	I:C0032405
ADP	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
PARP	B:C0032405
-	I:C0032405
1	I:C0032405
)	O
using	O
structure	O
based	O
design	O
approach	O
.	O

Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	O
for	O
aldose	O
reductase	I:C0002003
(	O
ALR2	O
)	O
and	O
poly	O
(	I:C0032405
ADP	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
PARP	O
-	I:C0032405
1	I:C0032405
)	O
using	O
structure	B:C0678594
based	O
design	O
approach	O
.	O

Clinical	B:C0008972
studies	I:C0008972
have	O
revealed	O
that	O
diabetic	O
retinopathy	I:C0011884
is	O
a	O
multifactorial	O
disorder	O
.	O

Clinical	O
studies	I:C0008972
have	O
revealed	O
that	O
diabetic	B:C0011884
retinopathy	I:C0011884
is	O
a	O
multifactorial	O
disorder	O
.	O

Clinical	O
studies	I:C0008972
have	O
revealed	O
that	O
diabetic	O
retinopathy	I:C0011884
is	O
a	O
multifactorial	O
disorder	B:C0012634
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	B:C0002003
and	O
PARP	O
-	I:C0032405
1	I:C0032405
co-occur	O
in	O
retinal	O
cells	O
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	I:C0011884
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	O
and	O
PARP	B:C0032405
-	I:C0032405
1	I:C0032405
co-occur	O
in	O
retinal	O
cells	O
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	I:C0011884
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
co-occur	O
in	O
retinal	B:C0035298
cells	O
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	I:C0011884
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
co-occur	O
in	O
retinal	O
cells	B:C0007634
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	I:C0011884
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
co-occur	O
in	O
retinal	O
cells	O
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	B:C0087111
of	O
diabetic	O
retinopathy	I:C0011884
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
co-occur	O
in	O
retinal	O
cells	O
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	O
of	O
diabetic	B:C0011884
retinopathy	I:C0011884
.	O

To	O
find	O
the	O
dual	O
inhibitors	B:C0014432
of	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
,	O
the	O
structure	O
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	O
.	O

To	O
find	O
the	O
dual	O
inhibitors	O
of	O
ALR2	B:C0002003
and	O
PARP	O
-	I:C0032405
1	I:C0032405
,	O
the	O
structure	O
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	O
.	O

To	O
find	O
the	O
dual	O
inhibitors	O
of	O
ALR2	O
and	O
PARP	B:C0032405
-	I:C0032405
1	I:C0032405
,	O
the	O
structure	O
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	O
.	O

To	O
find	O
the	O
dual	O
inhibitors	O
of	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
,	O
the	O
structure	B:C0678594
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	O
.	O

To	O
find	O
the	O
dual	O
inhibitors	O
of	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
,	O
the	O
structure	O
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	B:C0033684
.	O

A	O
series	O
of	O
novel	O
thiazolidine	B:C1568506
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
(	O
thiazolidine	O
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	O
activities	I:C1152555
against	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
were	O
evaluated	O
.	O

A	O
series	O
of	O
novel	O
thiazolidine	O
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
(	O
thiazolidine	B:C1568506
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	O
activities	I:C1152555
against	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
were	O
evaluated	O
.	O

A	O
series	O
of	O
novel	O
thiazolidine	O
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
(	O
thiazolidine	O
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	B:C1152555
activities	I:C1152555
against	O
ALR2	O
and	O
PARP	O
-	I:C0032405
1	I:C0032405
were	O
evaluated	O
.	O

A	O
series	O
of	O
novel	O
thiazolidine	O
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
(	O
thiazolidine	O
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	O
activities	I:C1152555
against	O
ALR2	B:C0002003
and	O
PARP	O
-	I:C0032405
1	I:C0032405
were	O
evaluated	O
.	O

A	O
series	O
of	O
novel	O
thiazolidine	O
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
(	O
thiazolidine	O
-	I:C1568506
2,4	I:C1568506
-	I:C1568506
dione	I:C1568506
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	O
activities	I:C1152555
against	O
ALR2	O
and	O
PARP	B:C0032405
-	I:C0032405
1	I:C0032405
were	O
evaluated	O
.	O

The	O
experimental	B:C2825142
results	I:C2825142
showed	O
that	O
compounds	O
5	I:C1254351
b	I:C1254351
and	O
5f	O
,	O
with	O
2	O
-	O
chloro	O
and	O
4	O
-	O
fluoro	O
substitutions	O
,	O
showed	O
biochemical	O
activities	O
in	O
micromolar	O
and	O
submicromolar	O
range	O
(	O
IC50	O
1.34-5.03μM	O
)	O
against	O
both	O
the	O
targeted	O
enzymes	O
.	O

The	O
experimental	O
results	I:C2825142
showed	O
that	O
compounds	B:C1254351
5	I:C1254351
b	I:C1254351
and	O
5f	O
,	O
with	O
2	O
-	O
chloro	O
and	O
4	O
-	O
fluoro	O
substitutions	O
,	O
showed	O
biochemical	O
activities	O
in	O
micromolar	O
and	O
submicromolar	O
range	O
(	O
IC50	O
1.34-5.03μM	O
)	O
against	O
both	O
the	O
targeted	O
enzymes	O
.	O

The	O
experimental	O
results	I:C2825142
showed	O
that	O
compounds	O
5	I:C1254351
b	I:C1254351
and	O
5f	B:C1254351
,	O
with	O
2	O
-	O
chloro	O
and	O
4	O
-	O
fluoro	O
substitutions	O
,	O
showed	O
biochemical	O
activities	O
in	O
micromolar	O
and	O
submicromolar	O
range	O
(	O
IC50	O
1.34-5.03μM	O
)	O
against	O
both	O
the	O
targeted	O
enzymes	O
.	O

The	O
experimental	O
results	I:C2825142
showed	O
that	O
compounds	O
5	I:C1254351
b	I:C1254351
and	O
5f	O
,	O
with	O
2	O
-	O
chloro	O
and	O
4	O
-	O
fluoro	O
substitutions	O
,	O
showed	O
biochemical	O
activities	O
in	O
micromolar	O
and	O
submicromolar	O
range	O
(	O
IC50	O
1.34-5.03μM	O
)	O
against	O
both	O
the	O
targeted	O
enzymes	B:C0014442
.	O

The	O
structure	O
-	O
activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	B:C0014432
against	O
both	O
the	O
enzymes	O
provide	O
new	O
insight	O
into	O
the	O
binding	O
mode	O
of	O
the	O
inhibitors	O
to	O
the	O
active	O
sites	O
of	O
enzymes	O
.	O

The	O
structure	O
-	O
activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	O
against	O
both	O
the	O
enzymes	B:C0014442
provide	O
new	O
insight	O
into	O
the	O
binding	O
mode	O
of	O
the	O
inhibitors	O
to	O
the	O
active	O
sites	O
of	O
enzymes	O
.	O

The	O
structure	O
-	O
activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	O
against	O
both	O
the	O
enzymes	O
provide	O
new	O
insight	O
into	O
the	O
binding	B:C1167622
mode	O
of	O
the	O
inhibitors	O
to	O
the	O
active	O
sites	O
of	O
enzymes	O
.	O

The	O
structure	O
-	O
activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	O
against	O
both	O
the	O
enzymes	O
provide	O
new	O
insight	O
into	O
the	O
binding	O
mode	O
of	O
the	O
inhibitors	B:C0014432
to	O
the	O
active	O
sites	O
of	O
enzymes	O
.	O

The	O
structure	O
-	O
activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	O
against	O
both	O
the	O
enzymes	O
provide	O
new	O
insight	O
into	O
the	O
binding	O
mode	O
of	O
the	O
inhibitors	O
to	O
the	O
active	O
sites	O
of	O
enzymes	B:C0014442
.	O

The	O
positive	B:C1446409
results	O
of	O
the	O
biochemical	O
assay	O
suggest	O
that	O
these	O
compounds	O
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	I:C0011884
.	O

The	O
positive	O
results	O
of	O
the	O
biochemical	O
assay	B:C0005507
suggest	O
that	O
these	O
compounds	O
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	I:C0011884
.	O

The	O
positive	O
results	O
of	O
the	O
biochemical	O
assay	O
suggest	O
that	O
these	O
compounds	B:C1254351
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	O
of	O
diabetic	O
retinopathy	I:C0011884
.	O

The	O
positive	O
results	O
of	O
the	O
biochemical	O
assay	O
suggest	O
that	O
these	O
compounds	O
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	B:C0087111
of	O
diabetic	O
retinopathy	I:C0011884
.	O

The	O
positive	O
results	O
of	O
the	O
biochemical	O
assay	O
suggest	O
that	O
these	O
compounds	O
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	O
of	O
diabetic	B:C0011884
retinopathy	I:C0011884
.	O

